U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441993) titled 'Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL' on Feb. 03.
Brief Summary: This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naive patients with marginal zone lymphoma.
Study Start Date: Jan. 05
Study Type: INTERVENTIONAL
Condition:
Marginal Zone Lymphoma
Intervention:
DRUG: Orelabrutinib
Induction phase (cycle 1-6):
Orelabrutinib (150 mg)
Recruitment Status: RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Published by HT Digital Content Services with permiss...